Medical Tool
Fragility Fracture Decision Aid
Estimate 10-year risk of major osteoporotic and hip fractures using published hazard ratios. Visualize the impact of bisphosphonate treatment and explore CTFPHC screening recommendations for shared decision-making.
Demographics
Clinical Risk Factors
10-year risk
Out of 100 people like this patient over 10 years:
Treatment Effect
e.g., Alendronate, Risedronate, Zoledronic acid
Contraindicated in esophageal disorders, hypocalcemia, severe renal impairment (eGFR <30–35)
CTFPHC Screening Context
Risk assessment–first screening recommended for females ≥65 years. If pharmacotherapy is considered, request BMD (DXA femoral neck) and re-estimate risk.
Screening not recommended for females 40–64 or males ≥40 (CTFPHC 2023).
Use results to facilitate shared decision-making about potential benefits and harms of preventive pharmacotherapy.
Clinical decision support only. Approximation based on published hazard ratios — not the official FRAX® tool. See CTFPHC 2023 Guideline | Official FRAX®. Not a substitute for clinical judgment.